Drug patents in Europe: how long “protection” really lasts—and where it breaks down
If you’re building a pipeline, underwriting risk, or pricing a launch strategy, the phrase “patent protection” can feel like a comforting constant. In Europe, though, t…

Drug discovery timelines are getting longer—and the cost of waiting is rising. The industry has spent decades optimizing chemistry, biology, and clinical trial design, yet the bottleneck often isn’t scientific ambition. It’s time: the time to search, s…

The “Patent Expiration Cliff” Is Coming—So Why Are So Many Market Access Teams Still Waiting for It?
If you work in commercial market access, you’ve seen the pattern: a brand’s exclusivity window tightens, internal teams scramble, and contracting strat…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be a clean story: win the patent fight, launch early, capture premium margins, and ride the wave before competitors arrive.
But in t…

The clock is ticking—and “generic” isn’t a single moment. It’s a sequence.
In the race to launch true generics, most teams obsess over the filing date. But the real competitive edge comes from something more granular: mapping regulatory exclusivities…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

The real “winner” in pharma patent litigation isn’t the brand company—or the generic company. It’s the calendar.
When a drug approaches the end of its exclusivity, the industry doesn’t just ask, “Will the patent hold?” It asks, “How long can we delay g…

Consumers Don’t Just Pay for Pills—They Pay for Certainty. Here’s Why Branded Generics Still Command a “Trust Premium.”
If you’ve ever wondered why a “generic” can cost more than you expected—or why some branded generics seem to hold pricing power even…

AI is getting better at predicting your next move—whether you want it to or not.
In pharma, the competitive landscape is no longer just a map of pipelines and patents. It’s a living system of filings, label expansions, trial signals, manufacturing co…

Pharma teams don’t lose because they lack data.
They lose because they don’t see the right data—early enough.
That’s the core message behind “Read the Patent. Beat the Competition. The Intelligence Gap Most Pharma Teams Leave Open.” And it’s a gap that…